Welcome to our dedicated page for iBio SEC filings (Ticker: IBIO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on iBio's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into iBio's regulatory disclosures and financial reporting.
iBio, Inc. reports the initial beneficial ownership status of its Chief Medical Officer, Molly Carr, on Form 3. She is identified as an officer with the title Chief Medical Officer, and no share transactions or holdings are listed in the data provided. Remarks reference Exhibit 24 – Power of Attorney, indicating an authorization for actions taken on her behalf.
iBio, Inc. appointed endocrinologist Molly Carr, M.D., as Chief Medical Officer effective July 31, 2026, to lead global clinical strategy, medical affairs and regulatory initiatives for its obesity and cardiometabolic pipeline. She brings more than 30 years of clinical, academic and biopharmaceutical experience, including senior roles at Eli Lilly and GlaxoSmithKline.
Under an employment agreement, Dr. Carr will receive an annual base salary of $470,000 and an annual target cash bonus equal to 40% of salary. As a material inducement to join, she was granted a non-qualified stock option to purchase 430,000 shares at $1.40 per share, with 25% vesting after one year and the remainder in 36 monthly installments. If terminated without Cause or resigning for Good Reason, she may receive salary continuation, pro rata or target bonus, COBRA coverage, and, following a Sale Event, accelerated vesting of time-based equity awards, subject to conditions.
iBio, Inc. plans to hold its 2026 Annual Meeting of Stockholders on October 14, 2026, with stockholders of record at the close of business on September 1, 2026 entitled to vote. The specific time and location will be provided in the definitive proxy statement.
Because this meeting date is more than 30 days earlier than the 2025 annual meeting, previously disclosed proposal deadlines no longer apply. Stockholder proposals for inclusion in the proxy materials under Rule 14a-8 must be received by August 1, 2026. Proposals or director nominations not under Rule 14a-8, submitted under the company’s bylaws, must be received by July 27, 2026. To comply with universal proxy rules, stockholders soliciting proxies for alternative director nominees must provide the notice required by Rule 14a-19 by August 15, 2026, 60 days before the meeting date.
iBio, Inc. reported new preclinical results from an obese non-human primate study of IBIO-610, a potentially first-in-class Activin E antibody for obesity and related diseases. After a single dose, active Activin E in blood fell in all treated animals and stayed suppressed for eight weeks.
Active Activin E levels were reduced by 98% at week 4 and 97% at week 8 compared with baseline, with levels below the limits of the assay at both time points. The company states this supports the potential for strong pathway inhibition and an infrequently dosed, long-acting antibody.
The data also suggest IBIO-610 may promote fat-selective weight loss while preserving lean mass. In obese primates, adding IBIO-610 to semaglutide produced greater visceral and total fat loss and cut lean mass loss by 73% versus semaglutide alone, supporting its potential as both a stand-alone and GLP-1-complementary therapy. The full dataset will be presented at the 2026 EASD Annual Meeting in Milan.
iBio, Inc. director Elizabeth Stoner received a grant of stock options covering 60,000 shares of common stock. The options have an exercise price of 1.42 per share and expire on 2036-05-17. They vest monthly on a pro rata basis over 36 months, and following this award she holds 60,000 options in total.
iBio, Inc. reporting persons led by Logos Global Management state they beneficially own 0 shares of Common Stock and report 0% ownership. The filing lists Logos Global, Logos Global GP, Logos Global Master Fund, Logos GP and Arsani William and disclaims group membership. The reporting persons certified the holdings and signed the amendment on 05/15/2026.
iBio, Inc. amendment to a Schedule 13G/A reports that Point72 Asset Management, Point72 Capital Advisors Inc., and Steven A. Cohen each beneficially owned 0% of iBio common stock as of the close of business on 03/31/2026. The filing lists the reporting persons' registered business address and CUSIP 451033708, and is signed by an authorized person on 05/15/2026.
iBio, Inc. Schedule 13G/A shows EcoR1 Capital, LLC and related reporting persons beneficially own 1,583,000 shares of Common Stock, representing 4.6% of the class. The filing states the calculation is based on 34,543,561 shares outstanding as of February 9, 2026.
The filing lists shared voting and dispositive power for the reported positions and clarifies EcoR1 is the general partner of the funds while Oleg Nodelman is the control person. Signatures show the filing was executed on May 14, 2026.
iBio, Inc. ownership update: Cormorant Asset Management and Bihua Chen report beneficial ownership of 3,834,335 shares of common stock, representing 9.99% of the class. The holdings reflect shares issuable upon exercise of pre-funded and Series G warrants, subject to a 9.99% beneficial ownership limit. The filing cites 34,543,561 shares outstanding as of February 9, 2026. The Reporting Persons note up to 7,752,005 shares would be issuable upon exercise of the Warrants absent the ownership limitation; 3,570,000 Series H shares are excluded from the reported total.
iBio, Inc. Schedule 13G: Sirenia Capital Management and Alex Silverstein report beneficial ownership of 11,586,340 shares of Common Stock, representing 9.9% of the class based on 34,543,561 shares outstanding as of February 24, 2026.
The cover disclosure states the count includes 10,710,000 shares issuable upon exercise of warrants held by a managed account but notes those warrants are subject to a 9.99% Blocker, which caps exercise so the Reporting Persons cannot exercise to exceed 9.99%.